Innova Captab

Has Innova Captab declared dividend?

No Dividend History Available

Who are the peers of the Innova Captab?

Innova Captab's peers include Aarti Pharma, Strides Pharma, FDC, Supriya Lifesci., SPARC, Aarti Drugs, Sequent Sciences, Hikal, and Unichem Labs. Innova Captab has good growth and an excellent capital structure, with a 1-year return of 76.45%, while Strides Pharma leads with 104.24%.

Peers: The peers of Innova Captab are Aarti Pharma, Strides Pharma, FDC, Supriya Lifesci., SPARC, Aarti Drugs, Sequent Scien., Hikal, and Unichem Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aarti Pharma, FDC, Supriya Lifesci., and Hikal, while Average management risk is found at Innova Captab, Sequent Scien., and Unichem Labs. Good management risk is noted at Aarti Drugs. Growth is rated as Good for Innova Captab, while Below Average growth is seen at Aarti Pharma, Strides Pharma, FDC, Supriya Lifesci., SPARC, Aarti Drugs, Sequent Scien., Hikal, and the rest. Excellent capital structure is attributed to Aarti Pharma, FDC, Supriya Lifesci., and Innova Captab, while Average capital structure is found at Unichem Labs and Below Average at Strides Pharma, SPARC, Sequent Scien., and Hikal.<BR><BR>Return Snapshot: Strides Pharma has the highest 1-year return at 104.24%, while SPARC has the lowest at -31.15%. Innova Captab's 1-year return of 76.45% is significantly higher than SPARC's but lower than Strides Pharma's. Additionally, Aarti Drugs, Hikal, and SPARC have negative six-month returns.

What does Innova Captab do?

Innova Captab Ltd, a mid-cap company in the Pharmaceuticals & Biotechnology sector, reported net sales of ₹3,147 Cr and a net profit of ₹296 Cr for the quarter ending March 2025. The company has a market cap of ₹5,130 Cr, a P/E ratio of 41.00, and a debt-equity ratio of 0.28.

Overview: <BR>Innova Captab Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History: <BR>Innova Captab Ltd was incorporated in 2005 under the name 'Harun Health Care Private Limited' and later changed its name in 2010. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 3,147 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 296 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 5,130 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 41.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.28 <BR>Return on Equity: 13.37% <BR>Price to Book: 5.38 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Innova Captab?

The top shareholders of Innova Captab include promoter Manoj Lohariwala with 29.07%, public shareholder Gian Parkash Aggarwal with 21.65%, individual investors with 27.62%, mutual funds holding 10.75%, and foreign institutional investors at 0.34%.

The top shareholders of Innova Captab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Manoj Lohariwala, with a stake of 29.07%. Additionally, Gian Parkash Aggarwal is the highest public shareholder, holding 21.65%. Individual investors collectively own 27.62% of the company. Mutual funds have a presence through 9 schemes, holding 10.75%, while foreign institutional investors (FIIs) hold a smaller portion at 0.34%.

How big is Innova Captab?

As of 24th July, Innova Captab Ltd has a market capitalization of 5,150.00 Cr, with net sales of 1,243.67 Cr and a net profit of 128.25 Cr in the latest four quarters. The balance sheet for March 2025 shows shareholder's funds of 959.42 Cr and total assets of 1,568.17 Cr.

As of 24th July, Innova Captab Ltd has a market capitalization of 5,150.00 Cr, categorizing it as a Mid Cap company.<BR><BR>In the latest four quarters, Innova Captab reported net sales of 1,243.67 Cr and a net profit of 128.25 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 959.42 Cr and total assets of 1,568.17 Cr.

When is the next results date for Innova Captab?

The next results date for Innova Captab is August 7, 2025.

The next results date for Innova Captab is scheduled for August 7, 2025.

Is Innova Captab overvalued or undervalued?

As of November 6, 2025, Innova Captab is considered undervalued with an attractive valuation grade, featuring a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, indicating better growth potential compared to peers despite recent underperformance against the Sensex.

As of 6 November 2025, Innova Captab has moved from a fair to attractive valuation grade, indicating a more favorable outlook. The company is currently considered undervalued. Key ratios include a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, which suggests that the stock is priced reasonably relative to its growth potential.<BR><BR>In comparison to its peers, Innova Captab's PE ratio is higher than Sun Pharma's 35.02 but lower than Divi's Lab's significantly high 79.09, indicating a competitive position within the industry. Additionally, while Cipla has a more attractive PE of 22.27, Innova Captab's PEG ratio of 0.99 suggests it offers better growth at its current price. Despite recent underperformance against the Sensex, with a year-to-date return of -26.98% compared to the Sensex's 6.62%, the valuation metrics support a bullish outlook for the stock moving forward.

How has been the historical performance of Innova Captab?

Innova Captab has shown consistent growth over the past three years, with net sales rising from 926.38 Cr in Mar'23 to 1,243.68 Cr in Mar'25, and profit after tax increasing from 67.95 Cr to 128.26 Cr. The company's total assets and liabilities also expanded significantly during this period.

Answer:<BR>The historical performance of Innova Captab shows a consistent growth trajectory in key financial metrics over the past three years.<BR><BR>Breakdown:<BR>Innova Captab's net sales increased from 926.38 Cr in Mar'23 to 1,243.68 Cr in Mar'25, reflecting a strong upward trend. Total operating income followed suit, reaching 1,243.68 Cr in Mar'25, up from 926.38 Cr in Mar'23. The company's total expenditure also rose, from 812.73 Cr in Mar'23 to 1,057.52 Cr in Mar'25, driven by higher raw material costs and employee expenses. Operating profit (PBDIT) improved significantly, climbing from 122.85 Cr in Mar'23 to 198.21 Cr in Mar'25, while profit before tax increased from 91.80 Cr to 171.02 Cr in the same period. Consequently, profit after tax surged from 67.95 Cr in Mar'23 to 128.26 Cr in Mar'25, resulting in an earnings per share (EPS) growth from 14.16 to 22.41. The company's total assets expanded from 704.29 Cr in Mar'23 to 1,568.17 Cr in Mar'25, with total liabilities also increasing from 704.29 Cr to 1,568.17 Cr. Cash flow from operating activities showed variability but ended at 63.00 Cr in Mar'25, while cash flow from financing activities was positive at 91.00 Cr. Overall, Innova Captab has demonstrated robust growth in revenue and profitability, alongside a significant increase in assets and liabilities over the past three years.

Is Innova Captab technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish due to bearish momentum from the MACD and KST, despite some bullish strength in the RSI, indicating a cautious approach is warranted.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish momentum, while the daily moving averages also reflect a bearish outlook. The weekly RSI shows bullish strength, but this is countered by the bearish signals from the Bollinger Bands. Dow Theory indicates a mildly bullish trend on the weekly chart, but overall, the mixed signals suggest a cautious approach. The stock has underperformed significantly against the Sensex over multiple time frames, further supporting the bearish sentiment.

Are Innova Captab Ltd latest results good or bad?

Innova Captab Ltd's latest results show strong revenue growth of 18.38% QoQ and 42.29% YoY, along with a 42.06% increase in net profit. However, concerns about declining operating margins and rising costs suggest a cautious outlook for investors.

Innova Captab Ltd's latest results present a mixed picture. On one hand, the company achieved impressive topline growth, with revenue increasing by 18.38% quarter-on-quarter and a remarkable 42.29% year-on-year, reaching ₹450.29 crores. The net profit also saw a significant rise of 42.06% QoQ, amounting to ₹42.15 crores, which is a positive indicator of profitability.<BR><BR>However, there are concerns regarding the operating margins, which, despite showing a sequential improvement to 15.41%, remain below the levels seen in the previous year. The PAT margin has also contracted year-on-year from 10.81% to 9.36%, indicating rising costs, particularly in employee expenses and interest, which are outpacing revenue growth.<BR><BR>Additionally, the stock's technical indicators are bearish, with the share price trading below key moving averages, and there has been a gradual reduction in institutional holdings. This suggests that while the revenue growth is strong, the company's ability to manage costs and maintain profitability is under scrutiny.<BR><BR>In summary, while the revenue and profit growth are commendable, the challenges with margins and cost management raise questions about the overall health of the company, leading to a cautious outlook for investors.

Should I buy, sell or hold Innova Captab Ltd?

Why is Innova Captab Ltd falling/rising?

As of 06-Feb, Innova Captab Ltd's stock price is 706.55, down 1.0 (-0.14%), reflecting a downward trend with a total decline of -2.63% over the last three days and a year-over-year return of -25.38%. Despite some positive financial indicators, the stock faces negative sentiment and declining investor participation, suggesting poor long-term growth prospects.

As of 06-Feb, Innova Captab Ltd's stock price is currently at 706.55, reflecting a decrease of 1.0 (-0.14%). The stock has been experiencing a downward trend, having fallen for the last three consecutive days, resulting in a total decline of -2.63% during this period. This recent performance is compounded by a year-over-year return of -25.38%, indicating significant underperformance compared to the BSE500 index, which has seen a positive return of +7.07% over the same timeframe.<BR><BR>Despite some positive indicators, such as a strong ability to service debt with a low Debt to EBITDA ratio of 1.40 times and the highest quarterly net sales and operating profit margins, the overall sentiment remains negative. The stock's performance over the last month shows a decline of -2.97%, while the year-to-date performance is also down by -1.44%. Additionally, there has been a notable drop in investor participation, with delivery volume falling by -66.15% against the five-day average, suggesting a lack of confidence among investors.<BR><BR>While the stock is trading at a discount compared to its peers and has high institutional holdings at 20.34%, the long-term growth prospects appear poor, with an annual growth rate of operating profit at only 17.89% over the last five years. This combination of factors contributes to the stock's current decline, as it struggles to attract investor interest amidst a backdrop of underperformance in both the short and long term.

Which are the latest news on Innova Captab?